Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG)

Anti-Cancer Drugs

Volumn 7, Issue 6, 1996, Pages 636-641

  Cummings, Jeffrey ^a   Hadfield, John A ^b   Meikle, Ian ^a   McGown, Alan T ^b   Smyth, John F ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Anthracenyl amino acid conjugates; d(CGTACG); DNA binding; Molecular modeling; Topoisomerase I and II inhibitors

Indexed keywords

ANTHRACENE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; ISOMERASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA BINDING; DRUG DESIGN; MOLECULAR MODEL; PRIORITY JOURNAL;

AMINO ACIDS; ANTHRAQUINONES; ARGININE; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; MODELS, MOLECULAR; SERINE; TYROSINE;

EID: 0029864520     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608000-00003     Document Type: Article

References (20)

1. Meikle I, Cummings J, Macpherson JS, Hadfield JA, Smyth JF. Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates. Biochem Pharmacol 1995; 49: 1747-57.
2. Tewey KM, Rowe ZTC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1985; 226: 466-8.
3. Hsiang Y-H, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-8.
4. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8.
5. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 1993; 4: 533-43.
6. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781-5.
7. MacDonald TL, Lehnert EK, Loper JT, Chow KC, Ross WE. On the mechanism of interaction of topoisomerase II with chemotherapeutic agents. In: Potmesil M, Kohn KW, eds. DNA topoisomerases in cancer. New York: Oxford University Press 1991: 199-215.
8. Morjani H, Riou J-F, Nabiev I, Lavelle F, Manfait M. Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy. Cancer Res 1993; 53: 4784-90.
9. Neidle S, Pearl LH, Skelly JV. DNA structure and pertubation by drug binding. Biochem J 1987; 243: 1-113.
10. Wang AH-J, Ughetto G, Quigley GJ, Rich A. Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complex to d(CpGpTpApCpGp) at 1.2-A resolution. Biochemistry 1987; 26: 1152-63.
11. Fredrick CA, Williams LD, Ughetto G, et al. Structural comparison of anticancer drug-DNA complexes: Adriamycin and Daunomycin. Biochemistry 1990; 29: 2538-49.
12. Leonard GA, Brown T, Hunter WN. Anthracycline binding to DNA. High resolution structure of d(TGTACA) with 4′-epiadrimycin. Eur J Biochem 1992; 204: 69-74.
13. Brown JR, Neidle S. Computer modelling of anthracycline- and anthraquinone-DNA interactions. In: Lown JW, ed. Anthracycline and anthracenedione-based anticancer agents. Amsterdam: Elsevier 1988: 335-69.
14. Cummings J, Meikle I, Macpherson JS, Smyth JF. Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug sensitive and drug resistant human ovarian cancer cell lines determined by high-performance liquid chromatography. Cancer Chemother Pharmacol 1995; 37: 103-9.
15. Meikle I, Cummings J, Macpherson JS, Smyth JF. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Anti-Cancer Drug Des 1995; 10: 515-27.
16. Hertzberg RP, Busby RW, Carafina MJ, et al. Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labelling of the camptothecin binding site. J Biol Chem 1990; 265: 19287-95.
17. Monnot M, Mauffret O, Simon V, et al. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 1991; 266: 1820-9.
18. Baguley BC, Holdaway KM, Fray LM. Design of DNA interacalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst 1990; 82: 398-402.
19. Nabiev I, Chourpa I, Riou J-F, Nguyen CH, Lavelle F, Manfait M. Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives. Biochemistry 1994; 33: 9013-23.
20. Capranico G, Zunino F. Structural requirements for DNA topoisomerase II inhibition by anthracyclines. In: Pullman B, Jortner J, eds. Molecular basis of specificity in nucleic acid-drug interactions. Dordrecht: Kluwer 1990: 167-76.